GYRE
Gyre Therapeutics Inc

9,480
Mkt Cap
$738.88M
Volume
41,648.00
52W High
$14.42
52W Low
$6.11
PE Ratio
198.69
GYRE Fundamentals
Price
$7.57
Prev Close
$7.67
Open
$7.61
50D MA
$7.74
Beta
1.37
Avg. Volume
83,738.87
EPS (Annual)
$0.0481
P/B
6.75
Rev/Employee
$21.15M
Loading...
Loading...
News
all
press releases
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Receives Average Rating of "Hold" from Brokerages
Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) have received a consensus recommendation of "Hold" from the five ratings firms that are currently covering the stock, MarketBeat...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
Gyre Therapeutics (NASDAQ:GYRE) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen raised shares of Gyre Therapeutics from a "hold" rating to a "buy" rating in a report on Saturday...
MarketBeat·4d ago
News Placeholder
SBI Securities Co. Ltd. Purchases 108,670 Shares of Gyre Therapeutics, Inc. $GYRE
SBI Securities Co. Ltd. increased its holdings in Gyre Therapeutics, Inc. (NASDAQ:GYRE - Free Report) by 87.9% during the second quarter, according to its most recent disclosure with the SEC. The...
MarketBeat·6d ago
News Placeholder
Noble Financial Has Bearish Estimate for GYRE Q1 Earnings
Gyre Therapeutics, Inc. (NASDAQ:GYRE - Free Report) - Equities research analysts at Noble Financial dropped their Q1 2026 earnings per share (EPS) estimates for Gyre Therapeutics in a research note...
MarketBeat·8d ago
News Placeholder
Research Analysts Offer Predictions for GYRE FY2025 Earnings
Gyre Therapeutics, Inc. (NASDAQ:GYRE - Free Report) - Stock analysts at HC Wainwright boosted their FY2025 earnings per share (EPS) estimates for shares of Gyre Therapeutics in a research report...
MarketBeat·10d ago
News Placeholder
GYRE THERAPEUTICS, INC. Announces Advance In Q3 Income
(RTTNews) - GYRE THERAPEUTICS, INC. (GYRE) reported a profit for its third quarter that Increased, from the same period last year...
Nasdaq News: Markets·13d ago
News Placeholder
Gyre Therapeutics, Inc. (GYRE) Q3 Earnings Surpass Estimates
Gyre Therapeutics, Inc. (GYRE) delivered earnings and revenue surprises of +20.00% and -8.89%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·13d ago
News Placeholder
Guardant Health (GH) Reports Q3 Loss, Beats Revenue Estimates
Guardant Health (GH) delivered earnings and revenue surprises of +18.75% and +13.05%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·22d ago
News Placeholder
New Strong Sell Stocks for Oct. 17th
GYRE, DAR and CRLBF have been added to the Zacks Rank #5 (Strong Sell) List on October 17, 2025.
Zacks·1mo ago
News Placeholder
Strength Seen in Septerna, Inc. (SEPN): Can Its 7.0% Jump Turn into More Strength?
Septerna, Inc. (SEPN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·1mo ago

Latest GYRE News

View

Advertisement|Remove ads.

Advertisement|Remove ads.